Generic Name and Formulations:
Metformin HCl 500mg/5mL; oral soln; cherry or strawberry flavor.
Ranbaxy Pharmaceuticals, Inc.
Indications for RIOMET:
Adjunct to diet and exercise in type 2 diabetes.
Take with meals. Individualize. ≥17yrs: Monotherapy: initially 500mg (5mL) twice daily or 850mg (8.5mL) once daily; may increase by increments of 500mg at 1-week intervals or 850mg in divided doses at 2-week intervals. Or, may increase from 500mg twice daily to 850mg twice daily after 2 weeks. Max 2.55g/day (25.5mL) in 2–3 divided doses. Adding to insulin: initially 500mg once daily; may increase by 500mg increments at 1-week intervals; max 2.5g/day (25mL). Reduce insulin dose by 10–25% as needed. Concomitant sulfonylureas: see full labeling.
<10yrs: not recommended. Take with meals. Individualize. ≥10yrs: Monotherapy only: initially 500mg (5mL) twice daily; may increase by 500mg increments at 1-week intervals. Max 2g/day (20mL) in divided doses.
Severe renal impairment (eGFR <30mL/min/1.73m2). Metabolic acidosis, diabetic ketoacidosis.
Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment, concomitant use of certain drugs (eg, cationic drugs), ≥65yrs of age, undergoing radiological contrast study, surgery and other procedures, hypoxic states, and excessive alcohol intake; discontinue if lactic acidosis occurs. Discontinue at time of, or prior to intravascular iodinated contrast imaging in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart therapy if renally stable. Suspend therapy if dehydration occurs or before surgery. Avoid if clinical or lab evidence of hepatic disease. Assess renal function prior to starting and periodically thereafter; more frequently in elderly or if eGFR <60mL/min/1.73m2. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Monitor hematology (esp. serum Vit. B12 in susceptible patients). Pregnancy (Cat.B), nursing mothers: not recommended; consider using insulin instead.
Increased risk of lactic acidosis with topiramate, other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide, dichlorphenamide); monitor. Concomitant cationic drugs that interfere with renal tubular transport systems (eg, ranolazine, vandetanib, dolutegravir, cimetidine) may increase metformin levels; monitor. Avoid excessive alcohol intake (potentiates effects of metformin on lactate). Diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, sympathomimetics, calcium channel blockers, isoniazid, nicotinic acid, others may cause hyperglycemia. May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia. β-blockers may mask hypoglycemia. May affect or be affected by furosemide, nifedipine.
Diarrhea, nausea, vomiting, flatulence; rare: lactic acidosis (may be fatal).
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments